What is Noxxon’s NOX-E36?

What is Noxxon’s NOX-E36?

The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic in 2021. NOXXON plans to develop NOX-E36 in patients with solid tumors.

What is the Noxxon pipeline?

About NOXXON. NOXXON’s oncology-focused pipeline acts by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor micro-environment (TME), NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.

How does noxnoxxon work?

NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact.

When will NOX-E36 go back into the clinic?

The read-out from the third high-dose cohort is expected in early 2022. The company’s second clinical-stage asset, NOX-E36 is a TME asset targeting the innate immune system and is planned to go back into the clinic in 2021.